Everolimus

By Chapman T.M.   Perry C.M.  

Drugs, Vol. 64, Iss. 8, 2004-01 ,pp. : 861-872

Adis International

Access to resources Recommend Favorite

Everolimus: A Review of its Use in Renal and Cardiac Transplantation

By Dunn Christopher   Croom Katherine F.  

Drugs, Vol. 66, Iss. 4, 2006-01 ,pp. : 547-570

Adis International

Access to resources Recommend Favorite

Proliferation signal inhibitor toxicities after thoracic transplantation

By Ensor Christopher R   Doligalski Christina T  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 1, 2013-01 ,pp. : 63-77

Informa Healthcare

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

By Deenen Maarten  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1557-1565

Springer Publishing Company

Access to resources Recommend Favorite

The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines

By Ma Brigette   Lui Vivian   Hui Edwin   Lau Cecilia   Ho Kakiu   Ng Margaret   Cheng S.   Tsao Sai-Wah   Chan Anthony  

Investigational New Drugs, Vol. 28, Iss. 4, 2010-08 ,pp. : 413-420

Springer Publishing Company

Access to resources Recommend Favorite